Serrated Polyposis Syndrome

The World Health Organization (WHO) definition from 2019 requires either pattern:

“Above the rectum” means further up the bowel than its final straight section. Hyperplastic polyps, SSLs and TSAs all count. Conventional adenomas do not count towards these serrated-polyp thresholds, but still need appropriate removal.

Removing the polyps does not erase the diagnosis, because the tendency to form new ones remains. A person just below the thresholds may also need closer follow-up; the counts are not a sharp dividing line between risk and no risk.

US consensus: cumulative WHO diagnosis is a strong recommendation, Oxford Level 5. Recording polyp number, size and location is strong, Level 4. Pages 2 and 6, Tables 2–3.[2]

The pattern may only become clear when reports from several examinations are brought together. Subtle lesions can be hard to see, and pathology names have changed as understanding has improved.

SPS is often missed. The US review estimates it is found in about 1 in 250 screening colonoscopies. A study of people referred after a positive stool test found about 1 in 111. These are different screening populations, not estimates for everyone.[2]

Ask which reports established your diagnosis and whether older pathology needs review. We cannot reliably date an individual polyp.

US review, pages 1 and 4; diagnosis and documentation grades above.

The tiny glands are called crypts. A normal crypt is fairly straight. A hyperplastic polyp usually has a saw-toothed upper part. In an SSL, the serration can extend deeper and the base may widen or turn sideways.

Dysplasia means cells have become more abnormal under the microscope. It is not the same as invasive cancer, but it changes how urgently a lesion is managed and how closely the bowel is checked.

Pathologists can sometimes disagree between an SSL and a hyperplastic polyp. Both count towards SPS. Hyperplastic polyps 10 mm or larger may be managed like SSLs.

US review, pages 4–6 and Figure 1. The rectosigmoid cancer finding is on pages 6 and 8.[2]

Growth signals. Conventional adenomas often involve a change in APC. Many SSLs acquire a change in BRAF, a gene involved in cell-growth signals. These are usually changes within the polyp, rather than an inherited BRAF change throughout the body.

Genes switched off. Chemical tags called DNA methylation can silence protective genes. When this is widespread it is called CIMP, the CpG island methylator phenotype.

Loss of DNA repair. One gene that can be switched off is MLH1. Errors then build up, sometimes producing a cancer with microsatellite instability (MSI).

Why this differs from Lynch syndrome. Lynch syndrome usually involves an inherited change in a DNA-repair gene. In this serrated pathway, MLH1 is often switched off within the lesion. Similar biology does not mean the same inherited condition.

People with SPS can also develop conventional adenomas. Both kinds of lesion need attention. The serrated pathway is thought to account for about 15–30 in every 100 bowel cancers overall; that is not your personal cancer risk.[6][12]

The pooled evidence. The meta-analysis combined 36 studies and 2,788 people. It estimated cancer at SPS diagnosis in 14.7 in every 100, with a 95% confidence interval of 11.4–18.8 in 100. During surveillance the pooled estimate was 2.8 in every 100, across follow-up of varying length; it is not a fixed five-year risk.[3][2]

The review reports that surveillance cancers were found a mean of 28.9 months after surveillance began. That is the time to those cancers, not the average follow-up of everyone in the pooled studies.

Recent cohorts have reported lower rates, including no cancers in several studies. No observed cancer does not prove zero future risk.

The 3.1-in-100 result is explicitly a three-year estimate. The other listed results are five-year estimates, which may extend beyond median follow-up. Cohorts differ in their patients and protocols; these are not individual predictions.[2]

Why older figures can sound alarming

Older retrospective studies counted cancer at any time in the recorded history, not just at diagnosis: 47 of 296 people in Carballal’s study and 127 of 434 in IJspeert’s study. In Carballal’s study, 4 of the 47 cancers were found during surveillance, so 43 were found before surveillance began. IJspeert’s surveillance subset included 260 people and 2 cancers. Their overall counts cannot be relabelled “cancer already present at diagnosis”.[5][6]

IJspeert reported 1.9 cancers per 1,000 person-years of surveillance. This is a different measure from the estimated 1.5 in 100 over five years.[6]

The primary meta-analysis separately reports cancer before SPS diagnosis in 7.0 in every 100, across historical records of varying length. The US review prints 7.7 for that figure. These sources differ; neither is a future risk, and the before-diagnosis, diagnosis and surveillance percentages must not be added together.[3][2]

Advanced findings are a different outcome

Studies report advanced neoplasia—advanced polyps or cancer—in approximately 22 to 44 in every 100 people over five years. eviQ cites 21.6 in 100, while the international cohort reports 44 in 100. Definitions and populations differ. Most events were polyps. This combined outcome is not a cancer rate or a strictly polyp-only rate.[1][4]

The international cohort’s cancer estimate has a 95% confidence interval of 0–3.2 in 100 over five years. A confidence interval expresses statistical uncertainty; only two cancers were observed.[4]

Your polyp types, size, dysplasia, previous cancer, complete removal, preparation and follow-up matter. The US review describes higher risk with its Type 1 pattern (criterion 1 above), or both patterns, in some cohorts. The meta-analysis did not find a clear difference by subtype. The diagnostic pattern alone does not determine your next interval.[2]

Australian eviQ guidance calls for removal of all SSLs, TSAs and conventional adenomas, plus hyperplastic polyps at least 5 mm. Procedures may be repeated at 3–6-month intervals until two colonoscopies are clear. Clearance commonly takes 2–4 examinations.[1]

As international variation, the US review specifies all conventional adenomas, all serrated lesions above the sigmoid colon, and at least all rectosigmoid serrated lesions 5 mm or larger. Figure 2 also describes programmes using a 3 mm distal target. Your team chooses the appropriate target; the entire bowel is checked.[2]

Do not assume routine surveillance has begun while significant lesions still need removal. “Clear” does not mean no new polyps will ever form.

What can happen during a session?

The US review describes averages of 10–16 removals per clearing colonoscopy and 5–7 per surveillance colonoscopy in published studies. Your number may be very different. Staging removal over several procedures can be part of a safe plan, rather than a sign that treatment has failed.

US review, pages 7–8 and Figure 2. Endoscopic management when there is no cancer: strong, Oxford Level 3. Individual clearance size targets are narrative guidance, not separately graded recommendations.

The Australian default remains 1–2 years after clearance. Earlier checks may be needed for incomplete removal, inadequate preparation or higher-risk findings. British guidance also supports yearly or two-yearly follow-up according to findings: a strong recommendation, moderate-quality evidence, using its own grading system.[1][8]

The US consensus offers the following general framework after clearance. It is not a strictly validated algorithm, and a specialist must consider the whole examination.

The usual US schedule is strong, Oxford Level 3. The optional three-year extension is weak, Oxford Level 5, based on expert opinion and limited evidence. Do not extend your interval yourself.[2]

What the newer trial found

A separate trial analysed selected patients with low polyp burden after clearance. Advanced polyps were found in 5 of 72 people at two years and 8 of 59 at three years. No bowel cancer was detected at those examinations.

The trial could not establish that the longer interval was acceptably close to the shorter interval. It was inconclusive; it does not prove that three years is unsafe. Keeping the Australian usual schedule is a cautious interpretation.[7]

Trial: Results and Table 3, pages 4081–4082; Figure 2, page 4083. It is separate later evidence and has no Task Force recommendation grade. The consensus literature search ended in June 2025.

Will I need colonoscopies for life?

Usually SPS means long-term follow-up. A few clear examinations do not automatically end surveillance. Later in life, your doctor should review the benefit alongside your health, procedure risks and preferences.

Good preparation, a complete examination and an endoscopist experienced with serrated lesions are central. High-definition white-light imaging is recommended; dye or electronic image enhancement may also help. No technology replaces careful inspection.

The US benchmark is an SSL detection rate of at least 6% across routine examinations. It is an endoscopist quality measure, not the chance of seeing one of your lesions. You can ask: “Do you regularly manage SPS, and measure how well you detect serrated lesions?”

Cold snare uses a wire loop without heat and is preferred for most SSLs and hyperplastic polyps. A visibly dysplastic area may need a different approach. Some AI systems help detect adenomas more than serrated lesions; AI is not a substitute for expertise.

US recommendations: documented detection skill strong, Oxford Level 5; high-definition imaging strong, Level 3; cold snare preference strong, Level 3. Pages 6–8 and Table 2.

Before an operation for benign polyps

An advanced endoscopist may be able to remove lesions that appear difficult to manage. The US recommendation to seek that opinion before surgical referral is weak, Oxford Level 5. This is an important discussion before a major operation.

If surgery is needed, the amount of bowel removed depends on the distribution of polyps, cancer if present, and your circumstances. Options include removing a segment or most of the colon and joining the small bowel to the rectum. Remaining bowel still needs follow-up.[2]

SPS sometimes clusters in families. Studies report bowel cancer rates around five times the usual rate in close relatives, but this relative increase does not give an individual’s absolute chance or lifetime risk.

The US review quotes a relative risk of 5.4 and a standardised incidence ratio of 5.16 in older studies. These compare rates with reference populations. The yield of screening relatives has been mixed in small studies, so the ideal timing and benefit remain uncertain.

International variation. US guidance starts at the earliest of age 40, 10 years before the youngest family bowel cancer diagnosis, or 5 years before the youngest family SPS diagnosis. British guidance uses age 40 or 10 years before the SPS diagnosis, whichever is earlier: strong recommendation, moderate-quality evidence. These rules differ from the Australian rule above; your family’s plan should follow local advice.

US family-screening recommendation: weak, Oxford Level 4, page 10 and Table 2. eviQ does not assign this recommendation the US Oxford grade.[2][8]

Usually there is no routine genetic test that explains SPS alone. Testing may still be useful if another polyp pattern or the family history suggests an inherited syndrome.

Australian eviQ advises genetics or family cancer review in selected circumstances, including conventional adenomas or SPS in other family members. Referral for assessment does not automatically mean a blood test.[1]

International testing advice. The US thresholds include more than 10 conventional adenomas or more than 2 hamartomatous polyps, or a family history suggesting another hereditary bowel cancer syndrome. Your doctor may refer you to a family cancer clinic. Hamartomatous polyps are a different tissue type.

British guidance is broader. Diagnosis before age 50, several affected relatives or dysplasia may prompt gene-panel testing to exclude another polyposis syndrome. This is a weak recommendation, very-low-quality evidence, using the British grading system.[8]

In a study of 258 people with SPS who had testing, 4 had relevant gene changes: 3 in Lynch syndrome genes and 1 in RNF43. These findings show a low yield, not that testing is never worthwhile.

US selective-testing recommendation: strong, Oxford Level 3, page 4 and Table 2.[2]

Smoking has a strong association with SPS, but many people with SPS have never smoked. Stopping is advised for overall health. We do not yet have evidence that quitting changes the course of SPS itself; that is uncertainty, not a reason to keep smoking.[2]

If you smoke, ask your GP or pharmacist for help. Regular activity and a healthy weight support general health. A varied diet with fibre is reasonable, adjusted to your symptoms and medical needs.

For healthy adults, Australian alcohol guidance advises no more than 10 standard drinks a week and no more than 4 on any day. Less drinking lowers harm; your doctor may advise a lower limit. These are general health limits, not an SPS treatment.[9]

Smoking: US review, pages 5–6; narrative advice without a separate Oxford grade. Alcohol: NHMRC adult guideline.

Australian eviQ guidance asks doctors to consider aspirin for suitable adults aged 45–70. Evidence specifically in SPS is limited. Aspirin can cause bleeding or ulcers.

Ask your doctor whether the possible benefit outweighs the risks for you, especially if you take blood thinners or have had bleeding. Do not start aspirin for SPS yourself. It does not replace colonoscopy.

eviQ 1373, risk-management and aspirin evidence sections. No matching US Task Force Oxford grade is assigned.[1]